Viadur

Endometriosis, Iron Deficiency Anemia, Iron replacement therapy + 6 more

Treatment

20 Active Studies for Viadur

What is Viadur

Leuprolide

The Generic name of this drug

Treatment Summary

Leuprolide is a medication used to reduce the production of sex hormones by mimicking the effects of an important hormone in the body called gonadotropin-releasing hormone (GnRH). It is approved to treat advanced prostate cancer, endometriosis, and precocious puberty. It is usually administered as an injection every six months. Leuprolide was first approved in 1985 and is marketed under the brand name Lupron™ by Abbvie Endocrine Inc.

Lupron

is the brand name

image of different drug pills on a surface

Viadur Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Lupron

Leuprolide

1986

57

Effectiveness

How Viadur Affects Patients

Leuprolide is a medication that affects the body's hormones, such as testosterone and estradiol. In women, it can worsen symptoms like pain or bleeding, and long-term use can lead to a decrease in bone mineral density. It can also cause vision issues and an increased risk of cardiovascular disease. In men, it can cause tumour flare, hyperglycemia, diabetes, and other cardiovascular issues. In children with central precocious puberty, it can cause convulsions and mental health issues like irritability and anger.

How Viadur works in the body

Leuprolide affects the body by affecting the hypothalamic-pituitary-gonadal (HPG) axis. It does this by binding to receptors on the anterior pituitary gland, prompting the production of hormones like testosterone, dihydrotestosterone, estrone, and estradiol. Initially, this causes a spike in hormones, which can lead to side effects. After two to four weeks, the hormones decrease, leading to a therapeutic benefit. Once treatment is stopped, these effects are reversed.

When to interrupt dosage

The advised dosage of Viadur is based on the determined condition, such as Anger Management Therapy, Central Precocious Puberty (CPP) and Uterine Fibroids. The quantity of dosage differs, contingent upon the method of delivery (e.g. Intramuscular or Intramuscular; Topical) specified in the table underneath.

Condition

Dosage

Administration

Endometriosis

, 10.0 mg/mL, 7.5 mg, 3.75 mg, 22.5 mg, 30.0 mg, 11.25 mg, 15.0 mg, 5.0 mg/mL, 72.0 mg, 3.75 mg/mL, 7.5 mg/mL, 225.0 mg/mL, 75.0 mg/mL, 15.0 mg/mL, 11.25 mg/mL, 45.0 mg/mL, 450.0 mg/mL, 300.0 mg/mL, 30.0 mg/mL, 22.5 mg/mL, 45.0 mg, 42.0 mg, 0.42 mg/mg

, Kit, Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Kit - Subcutaneous, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection, powder, for suspension, extended release - Subcutaneous, Liquid, Liquid - Subcutaneous, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Solution, Solution - Subcutaneous, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intramuscular, Kit - Intramuscular; Topical, Intramuscular; Topical, Intramuscular; Oral; Topical, Kit - Subcutaneous; Topical, Subcutaneous; Topical, Kit - Intramuscular, Injection, emulsion, Injection, emulsion - Subcutaneous

Palliative Treatment

, 10.0 mg/mL, 7.5 mg, 3.75 mg, 22.5 mg, 30.0 mg, 11.25 mg, 15.0 mg, 5.0 mg/mL, 72.0 mg, 3.75 mg/mL, 7.5 mg/mL, 225.0 mg/mL, 75.0 mg/mL, 15.0 mg/mL, 11.25 mg/mL, 45.0 mg/mL, 450.0 mg/mL, 300.0 mg/mL, 30.0 mg/mL, 22.5 mg/mL, 45.0 mg, 42.0 mg, 0.42 mg/mg

, Kit, Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Kit - Subcutaneous, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection, powder, for suspension, extended release - Subcutaneous, Liquid, Liquid - Subcutaneous, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Solution, Solution - Subcutaneous, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intramuscular, Kit - Intramuscular; Topical, Intramuscular; Topical, Intramuscular; Oral; Topical, Kit - Subcutaneous; Topical, Subcutaneous; Topical, Kit - Intramuscular, Injection, emulsion, Injection, emulsion - Subcutaneous

Puberty, Precocious

, 10.0 mg/mL, 7.5 mg, 3.75 mg, 22.5 mg, 30.0 mg, 11.25 mg, 15.0 mg, 5.0 mg/mL, 72.0 mg, 3.75 mg/mL, 7.5 mg/mL, 225.0 mg/mL, 75.0 mg/mL, 15.0 mg/mL, 11.25 mg/mL, 45.0 mg/mL, 450.0 mg/mL, 300.0 mg/mL, 30.0 mg/mL, 22.5 mg/mL, 45.0 mg, 42.0 mg, 0.42 mg/mg

, Kit, Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Kit - Subcutaneous, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection, powder, for suspension, extended release - Subcutaneous, Liquid, Liquid - Subcutaneous, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Solution, Solution - Subcutaneous, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intramuscular, Kit - Intramuscular; Topical, Intramuscular; Topical, Intramuscular; Oral; Topical, Kit - Subcutaneous; Topical, Subcutaneous; Topical, Kit - Intramuscular, Injection, emulsion, Injection, emulsion - Subcutaneous

Uterine Fibroids

, 10.0 mg/mL, 7.5 mg, 3.75 mg, 22.5 mg, 30.0 mg, 11.25 mg, 15.0 mg, 5.0 mg/mL, 72.0 mg, 3.75 mg/mL, 7.5 mg/mL, 225.0 mg/mL, 75.0 mg/mL, 15.0 mg/mL, 11.25 mg/mL, 45.0 mg/mL, 450.0 mg/mL, 300.0 mg/mL, 30.0 mg/mL, 22.5 mg/mL, 45.0 mg, 42.0 mg, 0.42 mg/mg

, Kit, Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Kit - Subcutaneous, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection, powder, for suspension, extended release - Subcutaneous, Liquid, Liquid - Subcutaneous, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Solution, Solution - Subcutaneous, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intramuscular, Kit - Intramuscular; Topical, Intramuscular; Topical, Intramuscular; Oral; Topical, Kit - Subcutaneous; Topical, Subcutaneous; Topical, Kit - Intramuscular, Injection, emulsion, Injection, emulsion - Subcutaneous

symptom recurrence

, 10.0 mg/mL, 7.5 mg, 3.75 mg, 22.5 mg, 30.0 mg, 11.25 mg, 15.0 mg, 5.0 mg/mL, 72.0 mg, 3.75 mg/mL, 7.5 mg/mL, 225.0 mg/mL, 75.0 mg/mL, 15.0 mg/mL, 11.25 mg/mL, 45.0 mg/mL, 450.0 mg/mL, 300.0 mg/mL, 30.0 mg/mL, 22.5 mg/mL, 45.0 mg, 42.0 mg, 0.42 mg/mg

, Kit, Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Kit - Subcutaneous, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection, powder, for suspension, extended release - Subcutaneous, Liquid, Liquid - Subcutaneous, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Solution, Solution - Subcutaneous, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intramuscular, Kit - Intramuscular; Topical, Intramuscular; Topical, Intramuscular; Oral; Topical, Kit - Subcutaneous; Topical, Subcutaneous; Topical, Kit - Intramuscular, Injection, emulsion, Injection, emulsion - Subcutaneous

Prostatic Neoplasms

, 10.0 mg/mL, 7.5 mg, 3.75 mg, 22.5 mg, 30.0 mg, 11.25 mg, 15.0 mg, 5.0 mg/mL, 72.0 mg, 3.75 mg/mL, 7.5 mg/mL, 225.0 mg/mL, 75.0 mg/mL, 15.0 mg/mL, 11.25 mg/mL, 45.0 mg/mL, 450.0 mg/mL, 300.0 mg/mL, 30.0 mg/mL, 22.5 mg/mL, 45.0 mg, 42.0 mg, 0.42 mg/mg

, Kit, Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Kit - Subcutaneous, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection, powder, for suspension, extended release - Subcutaneous, Liquid, Liquid - Subcutaneous, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Solution, Solution - Subcutaneous, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intramuscular, Kit - Intramuscular; Topical, Intramuscular; Topical, Intramuscular; Oral; Topical, Kit - Subcutaneous; Topical, Subcutaneous; Topical, Kit - Intramuscular, Injection, emulsion, Injection, emulsion - Subcutaneous

confirmed by clinical features

, 10.0 mg/mL, 7.5 mg, 3.75 mg, 22.5 mg, 30.0 mg, 11.25 mg, 15.0 mg, 5.0 mg/mL, 72.0 mg, 3.75 mg/mL, 7.5 mg/mL, 225.0 mg/mL, 75.0 mg/mL, 15.0 mg/mL, 11.25 mg/mL, 45.0 mg/mL, 450.0 mg/mL, 300.0 mg/mL, 30.0 mg/mL, 22.5 mg/mL, 45.0 mg, 42.0 mg, 0.42 mg/mg

, Kit, Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Kit - Subcutaneous, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection, powder, for suspension, extended release - Subcutaneous, Liquid, Liquid - Subcutaneous, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Solution, Solution - Subcutaneous, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intramuscular, Kit - Intramuscular; Topical, Intramuscular; Topical, Intramuscular; Oral; Topical, Kit - Subcutaneous; Topical, Subcutaneous; Topical, Kit - Intramuscular, Injection, emulsion, Injection, emulsion - Subcutaneous

Iron Deficiency Anemia

, 10.0 mg/mL, 7.5 mg, 3.75 mg, 22.5 mg, 30.0 mg, 11.25 mg, 15.0 mg, 5.0 mg/mL, 72.0 mg, 3.75 mg/mL, 7.5 mg/mL, 225.0 mg/mL, 75.0 mg/mL, 15.0 mg/mL, 11.25 mg/mL, 45.0 mg/mL, 450.0 mg/mL, 300.0 mg/mL, 30.0 mg/mL, 22.5 mg/mL, 45.0 mg, 42.0 mg, 0.42 mg/mg

, Kit, Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Kit - Subcutaneous, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection, powder, for suspension, extended release - Subcutaneous, Liquid, Liquid - Subcutaneous, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Solution, Solution - Subcutaneous, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intramuscular, Kit - Intramuscular; Topical, Intramuscular; Topical, Intramuscular; Oral; Topical, Kit - Subcutaneous; Topical, Subcutaneous; Topical, Kit - Intramuscular, Injection, emulsion, Injection, emulsion - Subcutaneous

Iron replacement therapy

, 10.0 mg/mL, 7.5 mg, 3.75 mg, 22.5 mg, 30.0 mg, 11.25 mg, 15.0 mg, 5.0 mg/mL, 72.0 mg, 3.75 mg/mL, 7.5 mg/mL, 225.0 mg/mL, 75.0 mg/mL, 15.0 mg/mL, 11.25 mg/mL, 45.0 mg/mL, 450.0 mg/mL, 300.0 mg/mL, 30.0 mg/mL, 22.5 mg/mL, 45.0 mg, 42.0 mg, 0.42 mg/mg

, Kit, Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Kit - Subcutaneous, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection, powder, for suspension, extended release - Subcutaneous, Liquid, Liquid - Subcutaneous, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Solution, Solution - Subcutaneous, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intramuscular, Kit - Intramuscular; Topical, Intramuscular; Topical, Intramuscular; Oral; Topical, Kit - Subcutaneous; Topical, Subcutaneous; Topical, Kit - Intramuscular, Injection, emulsion, Injection, emulsion - Subcutaneous

Warnings

Viadur has six contra-indications and should not be used simultaneously with the ailments listed in the table below.

Viadur Contraindications

Condition

Risk Level

Notes

Vaginal Hemorrhage

Do Not Combine

Pregnant Women

Do Not Combine

Metrorrhagia

Do Not Combine

Breast Neoplasms

Do Not Combine

Liver Neoplasms

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Leuprolide may interact with Pulse Frequency

There are 20 known major drug interactions with Viadur.

Common Viadur Drug Interactions

Drug Name

Risk Level

Description

Amiodarone

Major

The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Amiodarone.

Anagrelide

Major

The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Anagrelide.

Arsenic trioxide

Major

The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Arsenic trioxide.

Artemether

Major

The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Artemether.

Asenapine

Major

The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Asenapine.

Viadur Toxicity & Overdose Risk

Leuprolide is generally safe with low toxicity, and mild side effects. Even after two years of taking doses as high as 20 mg/day, prostate cancer patients did not experience any additional adverse effects compared to those taking 1 mg/day.

image of a doctor in a lab doing drug, clinical research

Viadur Novel Uses: Which Conditions Have a Clinical Trial Featuring Viadur?

144 active clinical trials are presently being conducted to assess the efficacy of Viadur in alleviating symptoms of recurrence, Uterine Fibroids and Iron Deficiency Anemia.

Condition

Clinical Trials

Trial Phases

Iron Deficiency Anemia

20 Actively Recruiting

Phase 3, Not Applicable, Phase 2, Phase 1, Phase 4

symptom recurrence

0 Actively Recruiting

Puberty, Precocious

1 Actively Recruiting

Phase 3

Endometriosis

27 Actively Recruiting

Early Phase 1, Phase 2, Not Applicable, Phase 3, Phase 4

Prostatic Neoplasms

0 Actively Recruiting

confirmed by clinical features

0 Actively Recruiting

Palliative Treatment

1 Actively Recruiting

Phase 3

Iron replacement therapy

0 Actively Recruiting

Uterine Fibroids

13 Actively Recruiting

Phase 2, Early Phase 1, Phase 3, Not Applicable, Phase 4

Viadur Reviews: What are patients saying about Viadur?

5

Patient Review

1/16/2009

Viadur for Advanced Form of Prostate Cancer

I experienced hot flashes, sweating, some breast enlargement, no sex drive whatsoever, and a decrease in testicle size.

4.7

Patient Review

11/14/2008

Viadur for Advanced Form of Prostate Cancer

4.3

Patient Review

11/29/2008

Viadur for Advanced Form of Prostate Cancer

It's been tough to sleep since my surgery. Sometimes sleeping pills help, but it's a temporary solution at best. I had my prostate removed as well as five lymph nodes. Two of them showed cancer, but so far all of the tests are coming back negative.

4

Patient Review

4/27/2008

Viadur for Advanced Form of Prostate Cancer

3

Patient Review

3/16/2010

Viadur for Osteoporosis

This treatment is great. I'm grateful for modern medicine.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about viadur

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Clinical Trials for Viadur

Image of University Hospitals Cleveland Medical Center in Cleveland, United States.

Ketamine for Pelvic Pain

18 - 89
Female
Cleveland, OH

The purpose of this research study is to see if ketamine infusion during surgery can decrease pain after surgery. Ketamine is a medication commonly used as part of anesthesia during surgery and is approved by the US FDA. Patients will be randomized to either receive standard anesthesia with OR without ketamine. The surgical procedure will be the same regardless of which group patients are randomized to. After surgery, patients will be asked to rate their pain in the post-operative observation unit and at their two-week post-operative visit. No additional visits are required for participation in this study. The investigators estimate the surveys will take approximately 10 minutes to complete.

Phase 4
Waitlist Available

University Hospitals Cleveland Medical Center

Morgan Cheeks, MD

Have you considered Viadur clinical trials?

We made a collection of clinical trials featuring Viadur, we think they might fit your search criteria.
Go to Trials
Image of Hospital of the University of Pennsylvania in Philadelphia, United States.

Educational Video for Uterine Fibroids

18 - 55
All Sexes
Philadelphia, PA

Uterine fibroids are a common condition that can cause heavy and/or painful menstrual bleeding. There are many treatment options, but they vary in efficacy, side effects, short-term recovery and long-term implications for future fertility. Patients can have difficulty deciding between these options. In this study, the investigators will randomly assign patients seeking treatment for fibroids to receive an educational video on fibroids and their treatment, versus usual care (no video). The investigators will assess their decisional conflict with and without exposure to the video using a validated survey to see if exposure to the educational video helps them make decisions.

Recruiting
Has No Placebo

Hospital of the University of Pennsylvania

Anuja Dokras, MD

Image of University Health Network (UHN) in Toronto, Canada.

Mitapivat for Anemia

18+
All Sexes
Toronto, Canada

This is a prospective exploratory phase 2 study designed to evaluate the safety and efficacy of mitapivat in RBC membranopathies and CDAII, a rare sub type of anemia. Nine patients from Princess Margaret who are diagnosed with CDAII will be enrolled to the study. Patients will be in the trial for 57 weeks treatment weeks and a safety follow up week after 30 days from last dose. First 8 weeks will be dose escalating period followed by 48 weeks of fixed dose period. 57th week will be dose tapering week. Data collected from Princes Margaret will be incorporated to the main study conducted in EU for analysis. Overall, approximately 25 patients are expected to be enrolled: Approximately 16 patients at sites in the EU and approximately 9 patients in Canada.

Phase 2
Recruiting

University Health Network (UHN)

Agios Pharmaceuticals, Inc.

Have you considered Viadur clinical trials?

We made a collection of clinical trials featuring Viadur, we think they might fit your search criteria.
Go to Trials
Image of Alethios, Inc. in San Francisco, United States.

NettleEndo for Endometriosis

22 - 45
Female
San Francisco, CA

The goal of this clinical trial is to learn if a wearable brain stimulation device called NettleEndo can reduce chronic pelvic pain and improve wellbeing in women with endometriosis. The study also aims to assess the safety and usability of the device when used at home over several months. The main questions it aims to answer are: 1. Does at-home transcranial direct current stimulation (tDCS) reduce daily pain intensity in women with endometriosis? 2. Does the device also improve mood and sleep quality? Researchers will compare two groups-one receiving active brain stimulation and one receiving a sham (placebo) stimulation-to see if the active device provides greater improvements in symptoms. Participants will: 1. Use the NettleEndo device at home for 20 minutes per session, five times per week for 12 weeks 2. Be randomly assigned to receive either real or sham stimulation through the device 3. Complete daily and weekly symptom ratings through a mobile app 4. Be followed for 90 days after completing the intervention to monitor longer-term effects All activities are completed remotely using a smartphone app. Participants can contact the study team with questions at any time. The study is double-blind, meaning neither participants nor the researchers assessing outcomes will know who received active or sham treatment until the end of the trial.

Recruiting
Online Trial

Alethios, Inc.

Nirav Shah, MD, MPH

Samphire Group, Inc.

Image of Baylor College of Medicine in Hosuton, United States.

Dronabinol for Endometriosis

18 - 64
Female
Hosuton, TX

This exploratory, proof-of-concept study is a double-blind (participants and investigators will be blinded), placebo-controlled, randomized, two-arm clinical trial of Marinol \[dronabinol, synthetic Δ9-tetrahydrocannabinol (THC)\] for e endometriosis-associated chronic pelvic pain (endo-CPP) with a 2:1 allocation ratio. Up to 75 subjects will be enrolled in this pilot study and randomized to receive doses of THC (up to 30 mg/day), orally, over 8 weeks. This study will be conducted at a single site; it does not include any stratifications, and there is no interim analysis planned. Notably, the goal is to determine whether there is enough evidence of the safety of THC to support the development of later-phase clinical trials. Thus, detailed developmental plans are contingent on the outcomes of this study.

Phase 2
Waitlist Available

Baylor College of Medicine (+1 Sites)

Christopher Verrico, PhD in Pharmacology

Image of Weill Cornell Medical College in New York, United States.

Luspatercept for Clonal Cytopenia

18+
All Sexes
New York, NY

The purpose of this clinical trial is to test how well the drug luspatercept works in improving low blood cell counts in people with clonal cytopenias of uncertain significance (CCUS). The main questions the study seeks to answer include: * How many patients experience improvements in their low blood counts (red cells, platelets, or white cells) within 24 weeks, based on specific criteria for blood conditions like myelodysplastic syndromes (MDS)? * How long these improvements last before the condition worsens or changes. * The percentage of participants showing improvements at 12, 24, and 48 weeks. * How long it takes for the condition to progress to more severe diseases like myeloid disorders. * How long red blood cell responses last and how quickly these responses are seen. * The average change in hemoglobin levels over 24 weeks. * How many patients need blood transfusions during the study and how soon transfusions are required. * Changes in participants' well-being and energy levels based on a standardized questionnaire. * Monitoring for any side effects, including progression to MDS or leukemia, heart-related issues, or sudden increases in hemoglobin. Participants will: * Receive luspatercept as an injection every three weeks. * Visit the clinic every three weeks for treatment and monitoring.

Phase 2
Recruiting

Weill Cornell Medical College

Pinkal Desai, MD

Bristol-Myers Squibb

Have you considered Viadur clinical trials?

We made a collection of clinical trials featuring Viadur, we think they might fit your search criteria.
Go to Trials